Alivus Life Sciences reported a strong Q2 FY27 with revenue rising 16% YoY to Rs 682 crore. EBITDA saw a significant 47% surge to Rs 285 crore, backed by strong margins. The company remains net debt-free with Rs 1,012 crore in cash, while plans for its Solapur facility expansion remain on track for Q3 FY27.
Alivus Life Sciences Reports Strong Q2 FY27 Growth
Revenue: Rs 682 Cr (+16% YoY) | EBITDA: Rs 285 Cr (+47% YoY)
Reader Takeaway: Strong operational margins and net debt-free status bolster growth, while monitoring the upcoming Solapur facility remains critical.
What just happened
Alivus Life Sciences delivered a robust performance for the quarter ended September 30, 2026. The company reported a 16% year-on-year (YoY) rise in revenue to Rs 682 crore. EBITDA grew by 47% to Rs 285 crore, representing a 41.8% margin, though adjusted margins sit closer to 39.5% when accounting for one-time income of Rs 24-25 crore. Net profit for the quarter stood at Rs 197 crore.
Why this matters
For investors, the results highlight strong execution, particularly in the CDMO segment, which grew 32.3% sequentially to Rs 50 crore. With non-GPL business now contributing 79% of total revenue, the company is effectively diversifying its income stream. The firm remains in a comfortable liquidity position, maintaining a net debt-free balance sheet with cash and investments totaling Rs 1,012 crore.
Business and Strategy
Management emphasized the progress at the Solapur facility, with Phase 1 expected to be operational by Q3 FY27. This expansion is central to the company’s long-term growth strategy. Furthermore, the company continues its focus on high-barrier segments, including flow chemistry and particle engineering, supported by a global footprint of over 630 DMF and CEP filings.
Risks to watch
While the company successfully mitigated crude-oil-linked inflation in solvent costs through inventory management, raw material price volatility remains a key monitorable. Additionally, investors should track whether the company can maintain EBITDA margins within the guided 35-36% range as the product mix evolves in the second half of the fiscal year.
What to track next
The operationalization of the Solapur facility in the upcoming quarter will be the primary catalyst for long-term capacity growth. Analysts will also look for sustained demand in the CDMO pipeline, which the management expects to eventually contribute 12-15% of total revenues.